Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals

The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applicati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of labelled compounds & radiopharmaceuticals 2018-03, Vol.61 (3), p.141-153
Hauptverfasser: Notni, Johannes, Wester, Hans‐Jürgen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 153
container_issue 3
container_start_page 141
container_title Journal of labelled compounds & radiopharmaceuticals
container_volume 61
creator Notni, Johannes
Wester, Hans‐Jürgen
description The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry. The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.
doi_str_mv 10.1002/jlcr.3582
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1965261219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1965261219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</originalsourceid><addsrcrecordid>eNp1kc1O3DAUha2qCAbKoi-ALHVTFoHrn2Ti7qoRtKCRkEbTteWxb5gMSRzsRIhdH4Fn5EnwdIBFJVZXuuc7R1f3EPKVwRkD4OebxoYzkZf8E5kwUCpjQsrPZAKi4JksQRyQwxg3AEmTcp8ccMWkEEU5Ic0Cn_8-Deu6u6u7WzqskQbfIPUVDcbVvsXBNLSOfvA9xh906R9McJEaWo3DGJBa31nsB1r5sHUH0_k41Hbn7tcmtMbimDamiV_IXpUGHr_OI_Ln8mI5-53Nb35dzX7OMyvKkmdWcclgVSowAsHlRoqiEJVyFo11qEoHplTTqXGYwyrJhROMO5RGgCyqShyR77vcPvj7EeOg2zpabBrToR-jZqrIecE4Uwn99h-68WPo0nWaA1OQMyGmiTrdUTb4GANWug91a8KjZqC3FehtBXpbQWJPXhPHVYvunXz7eQLOd8BD3eDjx0n6ej5b_It8ARZmkx0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019051337</pqid></control><display><type>article</type><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Notni, Johannes ; Wester, Hans‐Jürgen</creator><creatorcontrib>Notni, Johannes ; Wester, Hans‐Jürgen</creatorcontrib><description>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry. The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</description><identifier>ISSN: 0362-4803</identifier><identifier>EISSN: 1099-1344</identifier><identifier>DOI: 10.1002/jlcr.3582</identifier><identifier>PMID: 29143368</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Bismuth isotopes ; Data processing ; Diagnosis ; Diagnostic systems ; Dosimeters ; Dosimetry ; Humans ; Industrial engineering ; Isotopes ; Manufacturing engineering ; Metals, Heavy - chemistry ; molecular imaging ; molecular radiotherapy ; Nuclides ; Organometallic Compounds - chemistry ; positron emission tomography ; Precision medicine ; Production costs ; Radioisotopes ; Radioisotopes - chemistry ; radionuclides ; Radiopharmaceuticals - chemical synthesis ; Radiopharmaceuticals - chemistry ; Radiopharmaceuticals - therapeutic use ; Rare diseases ; Terbium ; Terbium isotopes ; Theranostic Nanomedicine - methods ; Tracers ; Zirconium isotopes</subject><ispartof>Journal of labelled compounds &amp; radiopharmaceuticals, 2018-03, Vol.61 (3), p.141-153</ispartof><rights>Copyright © 2017 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright © 2018 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</citedby><cites>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</cites><orcidid>0000-0002-3964-3391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjlcr.3582$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjlcr.3582$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29143368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Notni, Johannes</creatorcontrib><creatorcontrib>Wester, Hans‐Jürgen</creatorcontrib><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><title>Journal of labelled compounds &amp; radiopharmaceuticals</title><addtitle>J Labelled Comp Radiopharm</addtitle><description>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry. The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</description><subject>Animals</subject><subject>Bismuth isotopes</subject><subject>Data processing</subject><subject>Diagnosis</subject><subject>Diagnostic systems</subject><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>Humans</subject><subject>Industrial engineering</subject><subject>Isotopes</subject><subject>Manufacturing engineering</subject><subject>Metals, Heavy - chemistry</subject><subject>molecular imaging</subject><subject>molecular radiotherapy</subject><subject>Nuclides</subject><subject>Organometallic Compounds - chemistry</subject><subject>positron emission tomography</subject><subject>Precision medicine</subject><subject>Production costs</subject><subject>Radioisotopes</subject><subject>Radioisotopes - chemistry</subject><subject>radionuclides</subject><subject>Radiopharmaceuticals - chemical synthesis</subject><subject>Radiopharmaceuticals - chemistry</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Rare diseases</subject><subject>Terbium</subject><subject>Terbium isotopes</subject><subject>Theranostic Nanomedicine - methods</subject><subject>Tracers</subject><subject>Zirconium isotopes</subject><issn>0362-4803</issn><issn>1099-1344</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1O3DAUha2qCAbKoi-ALHVTFoHrn2Ti7qoRtKCRkEbTteWxb5gMSRzsRIhdH4Fn5EnwdIBFJVZXuuc7R1f3EPKVwRkD4OebxoYzkZf8E5kwUCpjQsrPZAKi4JksQRyQwxg3AEmTcp8ccMWkEEU5Ic0Cn_8-Deu6u6u7WzqskQbfIPUVDcbVvsXBNLSOfvA9xh906R9McJEaWo3DGJBa31nsB1r5sHUH0_k41Hbn7tcmtMbimDamiV_IXpUGHr_OI_Ln8mI5-53Nb35dzX7OMyvKkmdWcclgVSowAsHlRoqiEJVyFo11qEoHplTTqXGYwyrJhROMO5RGgCyqShyR77vcPvj7EeOg2zpabBrToR-jZqrIecE4Uwn99h-68WPo0nWaA1OQMyGmiTrdUTb4GANWug91a8KjZqC3FehtBXpbQWJPXhPHVYvunXz7eQLOd8BD3eDjx0n6ej5b_It8ARZmkx0</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Notni, Johannes</creator><creator>Wester, Hans‐Jürgen</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3964-3391</orcidid></search><sort><creationdate>201803</creationdate><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><author>Notni, Johannes ; Wester, Hans‐Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Bismuth isotopes</topic><topic>Data processing</topic><topic>Diagnosis</topic><topic>Diagnostic systems</topic><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>Humans</topic><topic>Industrial engineering</topic><topic>Isotopes</topic><topic>Manufacturing engineering</topic><topic>Metals, Heavy - chemistry</topic><topic>molecular imaging</topic><topic>molecular radiotherapy</topic><topic>Nuclides</topic><topic>Organometallic Compounds - chemistry</topic><topic>positron emission tomography</topic><topic>Precision medicine</topic><topic>Production costs</topic><topic>Radioisotopes</topic><topic>Radioisotopes - chemistry</topic><topic>radionuclides</topic><topic>Radiopharmaceuticals - chemical synthesis</topic><topic>Radiopharmaceuticals - chemistry</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Rare diseases</topic><topic>Terbium</topic><topic>Terbium isotopes</topic><topic>Theranostic Nanomedicine - methods</topic><topic>Tracers</topic><topic>Zirconium isotopes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Notni, Johannes</creatorcontrib><creatorcontrib>Wester, Hans‐Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Notni, Johannes</au><au>Wester, Hans‐Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</atitle><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle><addtitle>J Labelled Comp Radiopharm</addtitle><date>2018-03</date><risdate>2018</risdate><volume>61</volume><issue>3</issue><spage>141</spage><epage>153</epage><pages>141-153</pages><issn>0362-4803</issn><eissn>1099-1344</eissn><abstract>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry. The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29143368</pmid><doi>10.1002/jlcr.3582</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3964-3391</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0362-4803
ispartof Journal of labelled compounds & radiopharmaceuticals, 2018-03, Vol.61 (3), p.141-153
issn 0362-4803
1099-1344
language eng
recordid cdi_proquest_miscellaneous_1965261219
source MEDLINE; Wiley Online Library Journals
subjects Animals
Bismuth isotopes
Data processing
Diagnosis
Diagnostic systems
Dosimeters
Dosimetry
Humans
Industrial engineering
Isotopes
Manufacturing engineering
Metals, Heavy - chemistry
molecular imaging
molecular radiotherapy
Nuclides
Organometallic Compounds - chemistry
positron emission tomography
Precision medicine
Production costs
Radioisotopes
Radioisotopes - chemistry
radionuclides
Radiopharmaceuticals - chemical synthesis
Radiopharmaceuticals - chemistry
Radiopharmaceuticals - therapeutic use
Rare diseases
Terbium
Terbium isotopes
Theranostic Nanomedicine - methods
Tracers
Zirconium isotopes
title Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re%E2%80%90thinking%20the%20role%20of%20radiometal%20isotopes:%20Towards%20a%20future%20concept%20for%20theranostic%20radiopharmaceuticals&rft.jtitle=Journal%20of%20labelled%20compounds%20&%20radiopharmaceuticals&rft.au=Notni,%20Johannes&rft.date=2018-03&rft.volume=61&rft.issue=3&rft.spage=141&rft.epage=153&rft.pages=141-153&rft.issn=0362-4803&rft.eissn=1099-1344&rft_id=info:doi/10.1002/jlcr.3582&rft_dat=%3Cproquest_cross%3E1965261219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019051337&rft_id=info:pmid/29143368&rfr_iscdi=true